Methods are provided for effectively distinguishing the abilities of a human liver and an extracorporeal liver in an extracorporeal liver perfusion system to extract cholate and, thus, measure relative liver function.
A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
2.
COMPARTMENTAL ANALYSIS OF EXTRACORPOREAL LIVER PERFUSION SYSTEMS
Methods are provided for effectively distinguishing the abilities of a human liver and an extracorporeal liver in an extracorporeal liver perfusion system to extract cholate and, thus, measure relative liver function.
A61M 60/113 - Extracorporeal pumps, i.e. the blood being pumped outside the patient’s body incorporated within extracorporeal blood circuits or systems in other functional devices, e.g. dialysers or heart-lung machines
A61M 60/30 - Medical purposes thereof other than the enhancement of the cardiac output
A61M 60/523 - Regulation using real-time patient data using blood flow data, e.g. from blood flow transducers
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
Simplified methods are provided for determining liver function based on a Compartmental Model (CM) method for analysis of various hepatic indices including cholate SHUNT test which closely approximates and elucidates the underlying physiology of hepatic uptake of cholate from systemic and portal circulations simultaneously.
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Simplified methods are provided for determining liver function based on a Compartmental Model (CM) method for analysis of various hepatic indices including cholate SHUNT test which closely approximates and elucidates the underlying physiology of hepatic uptake of cholate from systemic and portal circulations simultaneously.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
5.
METHODS FOR DETERMINING LIVER FUNCTION COMPRISING A MULTI-COMPARTMENTAL MODEL
Methods are provided for determining liver function based on a Compartmental Model (CM) method for analysis of cholate SHUNT test data which closely approximates and elucidates the underlying physiology of hepatic uptake of cholate from systemic and portal circulations simultaneously.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Diagnostic kits comprised of medical diagnostic reagents for testing of bodily fluids for use in disease detection, namely, liver function Medical laboratory services
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Diagnostic kits comprised of medical diagnostic reagents for testing of bodily fluids for use in disease detection, namely, liver function Medical laboratory services
10.
METHODS OF DEFINING FUNCTIONAL CHANGE AND SLOWING PROGRESSION IN CHRONIC LIVER DISEASE
Methods and compositions are provided for treatment of chronic liver diseases such as NASH, for example, in order to slow disease progression, and reduce portal-systemic shunting. Methods comprising cholate liver function tests and administration of a statin and a biguanide are provided. Compositions comprising a statin and a biguanide are also provided.
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
11.
METHODS OF DEFINING FUNCTIONAL CHANGE AND SLOWING PROGRESSION IN CHRONIC LIVER DISEASE
Methods and compositions are provided for treatment of chronic liver diseases such as NASH, for example, in order to slow disease progression, and reduce portal-systemic shunting. Methods comprising cholate liver function tests and administration of a statin and a biguanide are provided. Compositions comprising a statin and a biguanide are also provided.
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
Improved methods and kits are provided for non-invasively evaluating liver function of a patient including rapidly and efficiently processing, detecting, and quantifying distinguishable compounds from patient blood or serum samples. A method is provided for estimating risk of experiencing a clinical event in 1 year for an individual patient having a chronic liver disease. Methods for determining hepatic reserve in a subject are provided.
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Improved methods and kits are provided for non-invasively evaluating liver function of a patient including rapidly and efficiently processing, detecting, and quantifying distinguishable compounds from patient blood or serum samples. A method is provided for estimating risk of experiencing a clinical event in 1 year for an individual patient having a chronic liver disease. Methods for determining hepatic reserve in a subject are provided.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Diagnostic kits comprised of medical diagnostic reagents for testing of bodily fluids for use in disease detection, namely, liver function Medical test kits for liver function monitoring Medical testing for diagnostic or treatment purposes; Medical testing for diagnostic or treatment purposes in the field of liver function
